Live Cell Fluorescent Assays for SARS-CoV-2 protease activity and COVID-19 Drug Discovery
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 5R44AI165188-02
Grant search
Key facts
Disease
COVID-19Start & end year
20222024Known Financial Commitments (USD)
$300,000Funder
National Institutes of Health (NIH)Principal Investigator
THOMAS HUGHESResearch Location
United States of AmericaLead Research Institution
MONTANA MOLECULAR, LLCResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Diagnostics
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
SUMMARY STATEMENT The SARS-CoV-2 virus depends upon two proteases for replication, 3CLpro and PLpro. If one or both of these proteases can be blocked, COVID-19 infection can be effectively treated. Montana Molecular makes and sells live cell, fluorescent biosensor assays for disease research and drug discovery. In response to the COVID-19 pandemic, Montana Molecular applied its expertise and background in live cell assay development to build fluorescent biosensors for the SARS-CoV-2 main protease, 3CLpro. The prototype sensor described in this proposal demonstrates feasibility. Direct to Phase II support is requested here to speed the development of even brighter, more sensitive assays for the 3CLpro and PLpro proteases. These assays can be used in high throughput screening for compounds that inhibit the protease, and engage with their target in living, human cells. 406-539-7399 366 Gallatin Park Drive Suite A Bozeman, MT 59715